MYC and breast carcinoma: The proteasome degradation pathway of c-MYC, a frequently overexpressed oncogene in breast cancer, may also depend on SUMOylation; its SUMOylation at K326 results in its subsequent ubiquitylation and degradation by the proteasome (Fig. 2A) [105, 106].